Cargando…
Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fra...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Science Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253408/ https://www.ncbi.nlm.nih.gov/pubmed/28133468 http://dx.doi.org/10.11909/j.issn.1671-5411.2016.11.006 |